Patients who are taking bisphosphonates products (Fosamax, Actonel and Boniva) might have a lower risk of getting breast cancer.
A study published in the February issue of the British Journal of Cancer looked at the consumption of bisphosphonate products in 2,936 patients with invasive breast cancer and 2,975 patients without breast cancer. Using statistic analysis, the investigator found that patients who took bisphosphonate products have a reduced risk of getting breast cancer.
Furthermore, the longer the patients took the product, the greater the reduction in breast cancer risk.
Since this was only a retrospective, statistical analysis, a prospective, head-to-head, placebo-controlled trial is needed to confirm this finding.
Newcomb PA et.al. British Journal of Cancer (2010) 102, 799-802